SARC

OncoLens Virtual Tumor Board platform connects the best minds, therapies, and innovations in cancer care - in time to make a difference

Retrieved on: 
Friday, June 2, 2023
SARC, Partnership, Mayo Clinic, Surgeon, Education, Cancer, Sarcoma, Patient, Physician, Health, Pharmaceutical industry, Dentistry

ATLANTA, June 2, 2023 /PRNewswire-PRWeb/ -- OncoLens and SARC Strategic Partnership Drives Nationwide Initiative for Enhanced Sarcoma Patient Care

Key Points: 
  • This initiative is particularly impactful for providers and patients facing limited resources while tackling sarcoma—a rare and complex form of cancer.
  • This initiative is particularly impactful for providers and patients facing limited resources while tackling sarcoma—a rare and complex form of cancer.
  • The OncoLens Virtual Tumor Board platform will grant medical professionals across the country access to the invaluable insights of top sarcoma experts.
  • This partnership empowers SARC with the OncoLens platform— a powerful tool that unites experts and facilitates robust virtual discussions on complex cases.

SARC LAUNCHES NATIONAL VIRTUAL MULTIDISCIPLINARY TUMOR BOARD FOR SARCOMA, REPRESENTING NEARLY 20% OF CHILDHOOD CANCERS AND 1% OF ADULT CANCERS

Retrieved on: 
Tuesday, May 9, 2023
SARC, Cancer, Sarcoma, Mayo Clinic, Surgeon, Patient, Physician, ANN, Pharmaceutical industry, Dentistry

ANN ARBOR, Mich., May 9, 2023 /PRNewswire/ -- SARC (Sarcoma Alliance for Research Through Collaboration) is proud to announce that it has launched a national, virtual multidisciplinary sarcoma tumor board.

Key Points: 
  • ANN ARBOR, Mich., May 9, 2023 /PRNewswire/ -- SARC (Sarcoma Alliance for Research Through Collaboration) is proud to announce that it has launched a national, virtual multidisciplinary sarcoma tumor board.
  • The SARC Multidisciplinary Tumor Board (SMTB) brings together sarcoma experts, complementing and expanding the geographic reach of local or regional institutional tumor boards.
  • "In 2023 SARC proudly celebrates our twentieth year facilitating and driving team science," said Steven Young, President & CEO of SARC, "and this tumor board extends support to the broader clinical community."
  • For more information, or to submit cases for consideration, clinicians are directed to: https://sarctrials.org/education/sarc-tumor-board/ .

Cadmatic is Part of Consortium Leading EU-Funded SEUS Project for Smarter and More Productive Shipbuilding

Retrieved on: 
Thursday, January 12, 2023
Data Management, Technology, Manufacturing, Construction & Property, Professional Services, Maritime, Transport, Software, Engineering, Other Construction & Property, Finance, Smarter Planet, Applied science, Norwegian University of Science and Technology, Element, University, Part, NHL Stenden University of Applied Sciences, PLM, Organization, Growth, Consortium, Ulstein Group, SARC, Engineering, Business development, SEUS, Research, NHL, Innovation, Data management, Multimedia, CAE, Business, Medical device, Shipbuilding, EU

Cadmatic is part of a consortium of industrial companies and academic institutions that is leading the EU-funded Smart European Shipbuilding project (SEUS) that was launched 1 January 2023.

Key Points: 
  • Cadmatic is part of a consortium of industrial companies and academic institutions that is leading the EU-funded Smart European Shipbuilding project (SEUS) that was launched 1 January 2023.
  • View the full release here: https://www.businesswire.com/news/home/20230111005065/en/
    Cadmatic is Part of Consortium Leading EU-Funded SEUS Project for Smarter and More Productive Shipbuilding (Photo: Business Wire)
    The platform solution aims to slash the time needed for ship engineering by 30% and cut assembly times by an ambitious 20%.
  • Cadmatic is responsible for leading the technical coordination of the four-year-long SEUS project.
  • “We are proud to be leading the technical coordination and working alongside the other consortium partners on this ambitious project.

Healthcare Solutions Management Group, Inc. Appoints Dr. Enrique Saguil to Head Advance Care Medical Comprehensive Urgent Care Centers in Illinois

Retrieved on: 
Tuesday, December 21, 2021
Alternative medicine, Physician, U.S. Securities and Exchange Commission, HSH, Alternative, Patient, Sports medicine, GLEN, Advocate Sherman Hospital, Heart, University, 3D ultrasound, SEC, SARC, Health, Degenerative disease, Nutrition, HSHS, ACM, Meditation, HSMD, MD, Yoga, Company, Advocate, Family medicine, OTC, Security (finance), General practitioner, GLOBE, Paola Lattus, Medicine, Chiropractic, Acupuncture

The Company will tap his expertise to head the Advance Care Medical Comprehensive Urgent Care Centers opening in Illinois.

Key Points: 
  • The Company will tap his expertise to head the Advance Care Medical Comprehensive Urgent Care Centers opening in Illinois.
  • Dr. Enrique Saguilhas been a General Practice doctor in Libertyville, Illinois, where he has been affiliated with Advocate Sherman Hospital.
  • Dr. Enrique Saguil has already begun seeingpatients and overseeing clinicians at our Advance Care Medical Comprehensive Urgent Care Center at 2975 Showplace Drive in Naperville, IL.
  • The Company operates through its wholly owned operating subsidiaries: Advance Care Medical Holdings, Inc. (ACM), HSH Surgical, Inc. (HSHS), and HSH Medical Services, Inc. (HSHMS).

Healthcare Solutions Management Group, Inc. Announces its New Ticker Symbol: HSMD

Retrieved on: 
Thursday, December 2, 2021
HSMD, Patient, Heart, Security (finance), SARC, Paola Lattus, Company, HSH, Degenerative disease, GLEN, SEC, U.S. Securities and Exchange Commission, Physician, GLOBE, Health, OTC, Cardiac catheterization, ACM, HSHS, Century, Medicine

GLEN COVE, N.Y., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Healthcare Solutions Management Group, Inc. (OTC: HSMD)has announced its ticker symbol has changed from symbol VRTY to HSMD, effective Nov.26, 2021.

Key Points: 
  • GLEN COVE, N.Y., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Healthcare Solutions Management Group, Inc. (OTC: HSMD)has announced its ticker symbol has changed from symbol VRTY to HSMD, effective Nov.26, 2021.
  • Healthcare Solutions Management Group Inc. (HSMD) is an integrated healthcare company committed to empowering physicians and clinicians with efficient state-of-the-art diagnostic and therapeutic tools, providing all patients access to advanced, affordable, comprehensive care.
  • The Company operates through its wholly owned operating subsidiary Healthcare Solutions Holdings, Inc., and its wholly owned subsidiaries: Advance Care Medical Holdings, Inc. (ACM), HSH Surgical, Inc. (HSHS), and HSH Medical Services, Inc. (HSHMS).
  • HSHS is a physician-partnered development and management company of multi-specialty ambulatory surgical centers (SARC by HSH Surgical).

SARC Appoints Dr. Jonathan Fletcher To New Role of Chief Scientific Officer

Retrieved on: 
Friday, October 22, 2021
SARC, Science, Research, Director, Harvard Medical School, Cancer, Career development, Industry, NIH, Sarcoma, Ryukyu Kingdom, Hospital, CSO, Cone Health Women's Hospital, Clinical trial, Biomarker, Skull, Multimedia, Biostatistics, Toxicity, Extremities, ANN, Genetics, Pharmaceutical industry

SARC (Sarcoma Alliance for Research Through Collaboration) appoints Jonathan Fletcher, M.D.

Key Points: 
  • SARC (Sarcoma Alliance for Research Through Collaboration) appoints Jonathan Fletcher, M.D.
  • Dr. Fletcher also serves on the SARC Board of Directors and on its Scientific Steering, Career Development, and Discovery/Translation Committees.
  • As CSO, Dr. Fletcher will expand SARC commitments in sarcoma biology, discovery science, and biomarkers, thereby strengthening SARC's portfolio of clinical trials.
  • Dr. Fletcher will also serve as chief spokesperson for SARC's scientific strategy, translating sarcoma science for diverse audiences such as the NIH, patient advocates, sarcoma clinicians, and SARC industry partners.

Epithelioid Sarcoma Collaborative Publishes White Paper Outlining Challenges and Proposing Solutions to Improve Outcomes of Patients Facing Rare Cancer

Retrieved on: 
Tuesday, October 12, 2021
Epithelioid sarcoma, Ryukyu Kingdom, Adolescence, Adult, Cyst, Journal, Dermatology, Physician, Director, Multimedia, Survival, Diagnosis, Cancer, FACS, Biopsy, Sarcoma, MRI, Review, II, Malignancy, Knowledge, STS, Extremities, III, ES, Awareness, ANN, Partnership, Disease, Patient, Science, Research, SARC, Practitioner, Skull, Concurrent estate, White paper, Tissue, Medical imaging, Pharmaceutical industry, Medical device

There is very little information available about Epithelioid Sarcoma (ES).

Key Points: 
  • There is very little information available about Epithelioid Sarcoma (ES).
  • "Recommendations from the Epithelioid Sarcoma Collaborative: A White Paper" has now been published in the Journal of Oncology Navigation and Survivorship.
  • This white paper is the result of a partnership between the Epithelioid Sarcoma Collaborative and SARC (Sarcoma Alliance for Research Through Collaboration).
  • Epithelioid sarcoma (ES) is an uncommon soft tissue sarcoma (STS).

San Andreas Regional Center Notifies Current and Former Consumers of Data Breach Incident

Retrieved on: 
Friday, August 27, 2021
Nursing, Managed Care, General Health, Health, Mental Health, Technology, Security, Other Health, FBI, California Department, Breach, SARC, Pennsylvania, Privacy, Incidence, Acquisition, Diagnosis, Database, EST, UCI, FTC, Federal Trade Commission, Disability in Canada, Identity theft, Name, Virginia Department of Behavioral Health and Developmental Services, Theft, Suite, Identity, California Department of Developmental Services, Pennsylvania Avenue, Risk management, Medical device, Dietary supplement

Working with the California Department of Developmental Services, San Andreas Regional Center (SARC) provides advocacy, services, and support for individuals with developmental disabilities.

Key Points: 
  • Working with the California Department of Developmental Services, San Andreas Regional Center (SARC) provides advocacy, services, and support for individuals with developmental disabilities.
  • SARC announced today that it experienced a data breach that may involve the personal and protected health information of some individuals it serves.
  • After discovering the incident, SARC quickly took steps to secure and safely restore its systems and operations.
  • In addition, individuals seeking to contact SARC directly may write to 6203 San Ignacio Avenue, Suite 200, San Jose, CA 95119.

Global Soft Tissue Sarcoma Pipeline Insight Report 2021: Comprehensive Insights on Approx 100+ Companies and 130+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 10, 2021
Health, Pharmaceutical, Sarcoma, Soft-tissue sarcoma, SARC, Clinical medicine, Health, Epidemiology

This "Soft Tissue Sarcoma - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape.

Key Points: 
  • This "Soft Tissue Sarcoma - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Soft Tissue Sarcoma R&D.
  • This segment of the report provides insights about the different Soft Tissue Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue

Retrieved on: 
Tuesday, December 1, 2020
Sarcoma, Clear cell sarcoma, Melanoma, SARC, Neoplasms, Saras, Clinical medicine, Health

In partnership with Saras Cure and Sarcoma Alliance for Research through Collaboration (SARC) , Rafael will begin enrolling patients into the Simon two-stage design trial at sites across the United States.

Key Points: 
  • In partnership with Saras Cure and Sarcoma Alliance for Research through Collaboration (SARC) , Rafael will begin enrolling patients into the Simon two-stage design trial at sites across the United States.
  • Woods founded Saras Cure after Sara, her teenage daughter, was diagnosed with clear cell sarcoma.
  • Clear cell sarcoma is most often found in teens and young adults in their 20s.
  • Both Saras Cure and SARC share our passion in being a voice for those battling this rare disease.